Kazia Therapeutics Granted Nasdaq Compliance Extension
Company Announcements

Kazia Therapeutics Granted Nasdaq Compliance Extension

Kazia Therapeutics (KZIA) has released an update.

Kazia Therapeutics has received an extension from Nasdaq to meet the minimum bid price requirement after initially failing to comply. The company now has an additional 180 days to increase its share price to at least $1.00 for a minimum of 10 consecutive business days to maintain its listing. Although there is no immediate impact on its operations or listing status, there’s no guarantee that Kazia will achieve compliance within the new timeframe.

For further insights into KZIA stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskKazia Therapeutics Secures Nasdaq Compliance
TheFlyKazia Therapeutics management to meet with Maxim
TipRanks Auto-Generated NewsdeskKazia Therapeutics Advances Paxalisib with FDA Meeting
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App